[withdrawn] glofitamab in the treatment of diffuse large b-cell lymphoma (dlbcl)

Decision GLOFITAMAB IN THE TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) EAMS scientific opinion issued to Roche Products Limited for glofitamab as monotherapy in the treatment of adult

patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Get emails about this page THIS PUBLICATION WAS WITHDRAWN ON 14 NOVEMBER 2023 Withdrawn due to granting of

marketing authorisation. DOCUMENTS GLOFITAMAB: PUBLIC ASSESSMENT REPORT (PAR) PDF, 842 KB, 5 pages This file may not be suitable for users of assistive technology. Request an accessible

format. If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what

format you need. It will help us if you say what assistive technology you use. GLOFITAMAB: TREATMENT PROTOCOL - INFORMATION FOR HEALTHCARE PROFESSIONALS PDF, 315 KB, 19 pages This file may

not be suitable for users of assistive technology. Request an accessible format. If you use assistive technology (such as a screen reader) and need a version of this document in a more

accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use. GLOFITAMAB: TREATMENT PROTOCOL -

INFORMATION FOR PATIENTS PDF, 227 KB, 9 pages This file may not be suitable for users of assistive technology. Request an accessible format. If you use assistive technology (such as a screen

reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive

technology you use. GLOFITAMAB: INFORMATION FOR NHS MEDICAL DIRECTOR PDF, 134 KB, 4 pages This file may not be suitable for users of assistive technology. Request an accessible format. If

you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you

need. It will help us if you say what assistive technology you use. GLOFITIMAB: TREATMENT PROTOCOL INFORMATION ON PHARMACOVIGILANCE SYSTEM PDF, 176 KB, 5 pages This file may not be suitable

for users of assistive technology. Request an accessible format. If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format,

please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use. DETAILS For the full EAMS indication please see

section 4.1 of the Treatment protocol: Information for healthcare professionals. The scientific opinion includes: * a public assessment report (PAR) * a treatment protocol: * for healthcare

professionals * for patients * on the pharmacovigilance system * Information for NHS Medical Directors UPDATES TO THIS PAGE Published 5 July 2023 SIGN UP FOR EMAILS OR PRINT THIS PAGE Get

emails about this page Print this page